Biggest News Aggregation in the World
๐Ÿ“ฐ Leukemia News

Page 159 - Leukemia News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Leukemia. Real-time updates on events, politics, business and more.

Novartis Pharma AG: Novartis Scemblix, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week
United States East Hanover Isabella Zinck Jeff Legos Amy Wolf Nicole Zinsli Somm

Spotlight on Stanley Lee

For Dr. Stanley Lee, science doesnโ€™t have to be a work of art. More than anything, the blood cancer researcher at Fred Hutchinson Cancer Research Center believes research needs to be collaborative, precise and โ€” most important โ€” without delay, especially in cancer where, ultimately, research can save lives.
Fred Hutch Stanley Lee Robert Hood Fred Hutch News Service Fred Hutchinson Cancer Research Center Robert Hood Fred Hutch News

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.
United States Monical Guzman Gail Roboz Emily Henderson Nature Communications Division Of Hematology Medical Oncology

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

New research may open a window to treating aggressive form of B-cell acute lymphoblastic leukemia

Survival has improved greatly in children with acute lymphocytic leukemia (ALL). But a certain form of ALL that occurs mostly in babies is still very lethal, with a survival rate below 50 percent: B-cell acute lymphoblastic leukemia with rearrangements of the mixed lineage leukemia gene, or MLL B-ALL.
United States Scott Armstrong Grant Rowe Emily Henderson Hematopoietic Stem Cell Transplant Program Blood Disorders Center

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science